BioCentury: ShangPharma, Icahn in R&D Deal

BioWorld: Other news to note

Endpoints: AveXis wants $400M more for promising SMA gene therapy; ShangPharma partners with Icahn School of Medicine at Mount Sinai

BioSpace: ShangPharma Innovation and Icahn School of Medicine at Mount Sinai Forge Translational Research Collaboration

ShangPharma Innovation and Icahn School of Medicine at Mount Sinai Forge Translational Research Collaboration

ed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit.